| Cassandra Ann Doucet, | |
|
1700 Medical Center Pkwy, Murfreesboro, TN 37129-2245 | |
| (615) 995-5468 | |
| Not Available |
| Full Name | Cassandra Ann Doucet |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 7 Years |
| Location | 1700 Medical Center Pkwy, Murfreesboro, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962934653 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 0000060049 (Tennessee) | Secondary |
| 207R00000X | Internal Medicine | 60049 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Tennova Healthcare-shelbyville | Shelbyville, TN | Hospital |
| Vanderbilt University Medical Center | Nashville, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anova Medical Associates | 8325372741 | 112 |
News Archive
The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.
Metastatic cancer cells, which can migrate from primary tumors to seed new malignancies, have thus far been resistant to the current arsenal of anticancer drugs.
The incidence of Barrett's esophagus in the UK has doubled in recent years, but the incidence of gastroesophageal reflux disease is stable, study findings reveal.
Merck, known outside the United States and Canada as MSD, today announced that the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study of TREDAPTIVE(extended-release niacin/laropiprant) did not meet its primary endpoint.
› Verified 8 days ago
| Entity Name | Saint Thomas Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437194669 PECOS PAC ID: 1557269354 Enrollment ID: O20031230000470 |
News Archive
The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.
Metastatic cancer cells, which can migrate from primary tumors to seed new malignancies, have thus far been resistant to the current arsenal of anticancer drugs.
The incidence of Barrett's esophagus in the UK has doubled in recent years, but the incidence of gastroesophageal reflux disease is stable, study findings reveal.
Merck, known outside the United States and Canada as MSD, today announced that the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study of TREDAPTIVE(extended-release niacin/laropiprant) did not meet its primary endpoint.
› Verified 8 days ago
| Entity Name | App Of Tennessee Hm, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396160768 PECOS PAC ID: 5395960694 Enrollment ID: O20140630001088 |
News Archive
The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.
Metastatic cancer cells, which can migrate from primary tumors to seed new malignancies, have thus far been resistant to the current arsenal of anticancer drugs.
The incidence of Barrett's esophagus in the UK has doubled in recent years, but the incidence of gastroesophageal reflux disease is stable, study findings reveal.
Merck, known outside the United States and Canada as MSD, today announced that the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study of TREDAPTIVE(extended-release niacin/laropiprant) did not meet its primary endpoint.
› Verified 8 days ago
| Entity Name | Anova Medical Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659849537 PECOS PAC ID: 8325372741 Enrollment ID: O20190618003690 |
News Archive
The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.
Metastatic cancer cells, which can migrate from primary tumors to seed new malignancies, have thus far been resistant to the current arsenal of anticancer drugs.
The incidence of Barrett's esophagus in the UK has doubled in recent years, but the incidence of gastroesophageal reflux disease is stable, study findings reveal.
Merck, known outside the United States and Canada as MSD, today announced that the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study of TREDAPTIVE(extended-release niacin/laropiprant) did not meet its primary endpoint.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Cassandra Ann Doucet, 300 20th Ave N Ste 403, Nashville, TN 37203-5180 Ph: (615) 284-7224 | Cassandra Ann Doucet, 1700 Medical Center Pkwy, Murfreesboro, TN 37129-2245 Ph: (615) 995-5468 |
News Archive
The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.
Metastatic cancer cells, which can migrate from primary tumors to seed new malignancies, have thus far been resistant to the current arsenal of anticancer drugs.
The incidence of Barrett's esophagus in the UK has doubled in recent years, but the incidence of gastroesophageal reflux disease is stable, study findings reveal.
Merck, known outside the United States and Canada as MSD, today announced that the HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) study of TREDAPTIVE(extended-release niacin/laropiprant) did not meet its primary endpoint.
› Verified 8 days ago
Joyline D James, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 3400 Lebanon Rd, Murfreesboro, TN 37129 Phone: 615-867-6000 | |
Vishant Shah, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3400 Lebanon Rd, Murfreesboro, TN 37129 Phone: 615-225-2493 | |
Dr. Valarie Readus Moore, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 3400 Lebanon Road, Murfreesboro, TN 37129 Phone: 615-867-6000 | |
Richard Earl Parrish, MD, FCCP Internal Medicine Medicare: Medicare Enrolled Practice Location: 1800 Medical Center Pkwy Ste 310, Murfreesboro, TN 37129 Phone: 615-849-9868 Fax: 615-898-1882 | |
Joseph Scott, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1272 Garrison Drive, Murfreesboro, TN 37129 Phone: 615-867-8010 Fax: 615-867-7945 | |
Dr. Vlada Melekhin, M.D., M.P.H. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1800 Medical Center Pkwy Ste 400, Murfreesboro, TN 37129 Phone: 615-396-6800 | |
Dr. Donald Parker Patterson, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1800 Medical Center Parkway, Depaul Bldg. Ste. 400, Murfreesboro, TN 37129 Phone: 615-396-6800 Fax: 615-396-6801 |